Get the Stockscreener App
25.60
0.47%
-0.12
After Hours:
25.60
Mirum Pharmaceuticals Inc stock is currently priced at $25.60, with a 24-hour trading volume of 309.97K.
It has seen a -0.47% decreased in the last 24 hours and a +1.55% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $25.60 pivot point. If it approaches the $24.81 support level, significant changes may occur.
Previous Close:
$25.72
Open:
$25.82
24h Volume:
309.97K
Market Cap:
$1.21B
Revenue:
$186.37M
Net Income/Loss:
$-163.42M
P/E Ratio:
-5.9593
EPS:
-4.2958
Net Cash Flow:
$-91.05M
1W Performance:
+4.53%
1M Performance:
+1.55%
6M Performance:
-9.83%
1Y Performance:
-6.02%
1D Range:
$25.18
$25.92
52W Range:
$23.14
$35.56
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
950 Tower Lane, Suite 300, Foster City
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks Investment Research
Some Bubbles Are Starting To Pop
Seeking Alpha
Analyst Ratings For Mirum Pharmaceuticals
Benzinga
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
Benzinga
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Mirum Pharmaceuticals Inc (MIRM) Revenue 2024
MIRM reported a revenue (TTM) of $186.37 million for the quarter ending December 31, 2023, a +141.85% rise year-over-year.
Mirum Pharmaceuticals Inc (MIRM) Net Income 2024
MIRM net income (TTM) was -$163.41 million for the quarter ending December 31, 2023, a -20.45% decrease year-over-year.
Mirum Pharmaceuticals Inc (MIRM) Cash Flow 2024
MIRM recorded a free cash flow (TTM) of -$91.05 million for the quarter ending December 31, 2023, a +24.38% increase year-over-year.
Mirum Pharmaceuticals Inc (MIRM) Earnings per Share 2024
MIRM earnings per share (TTM) was -$4.0195 for the quarter ending December 31, 2023, a -0.09% decline year-over-year.
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
0.56%
3.58%
Cap:
|
Volume (24h):